We read the Review by Željko Reiner (Statins in the primary prevention of cardio vascular disease. Nat. Rev. Cardiol. doi:10.1038 / nrcardio.2013 1 with great interest. We are particularly interested in the role of statins in primary prevention of cardio vascular disease (CVD) in individuals at low cardiovascular risk.
As was well discussed in the Review, clear evidence exists to support the use of statins for primary prevention in highrisk individ uals.
1 A risk of developing CVD >20% over 10 years, or >10% over 5 years, is widely used as the cutoff point for prescribing statins.
2 However, the use of statins in low risk individ uals is controversial. A meta analysis from the Cholesterol Treatment Trialists' (CTT) Collaborators showed that statins reduce the risk of major cardio vascular events by about 20% across all levels of baseline risk (even in individuals with a 5year risk of major vascular events that is <10%).
3 The CTT Collaborators suggested that the current guidelines for CVD preven tion might need to be reconsidered.
3 Their study raises enthusiasm for statins in the primary prevention of CVD in individuals at low cardiovascular risk. In fact, some have advocated treating 'all comers' with statins. 4 Several issues, however, should be consid ered before advocating the widespread use of statins in individuals at low risk, such as the feasibility, desirability, and costeffectiveness of such a strategy, and the quality of life for apparently healthy individuals who are pre scribed lifelong drug therapy. Also i mportant are potential adverse effects of statins. 2, 5, 6 We agree that statins are likely to be ben eficial to patients with low cardio vascular risk calculated using tradi tional riskassessmen t algorithms, such as the Framingham Risk Score and the SCORE (Systematic COronar y Risk Estimation) charts. Coronary artery calcium (CAC) scoring has been shown to predict coronary events beyond the use of the traditional Framingham Risk Score, with a high CAC burden (≥300) being associated with increased risk. 8, 9 Data from comparative effectiveness studies have suggested that quantification of CAC is a superior method to measurement of the hsCRP level for improving risk assessment.
10 Investigators in the St. Francis Heart Study 11 enrolled patients with an elevated CAC level (CAC >80 th percentile) and randomly allocated them to receive 20 mg of atorvastatin daily or placebo. The overall result did not meet sta tistical significance (P = 0.08) because of the limited power of the trial, but showed that atorvastatin significantly reduced the com posite rate of adverse events from c oronary heart disease by 30%.
11
In conclusion, the use of statins for primary prevention in lowrisk individuals remains an ambiguous area. We believe that additional riskstratification options (such as measurement of the hsCRP level and CAC scoring) should be explored in this popula tion. A new riskassessment algorithm that includes the traditional risk measures, but also incorporates these novel markers should be developed to identify lowrisk patients and guide the prophylactic use of statins. 
